0IL Stock Overview A drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. More details
Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
IntelGenx Technologies Corp. Competitors Price History & Performance
Summary of share price highs, lows and changes for IntelGenx Technologies Historical stock prices Current Share Price US$0.14 52 Week High US$0.21 52 Week Low US$0.061 Beta 2.6 1 Month Change 0% 3 Month Change 20.17% 1 Year Change 16.26% 3 Year Change -57.82% 5 Year Change -61.35% Change since IPO -77.55%
Recent News & Updates IntelGenx Technologies Corp. Announces Resignation of Dwight Gorham as Chief Executive Officer IntelGenx Technologies Corp. announced delayed 10-Q filing Aug 15
ATAI Life Sciences AG entered into an agreement of purchase and sale to acquire the Assets of IntelGenx Technologies Corp. (OTCPK:IGXT). May 30
ATAI Life Sciences AG entered into an agreement of purchase and sale to acquire the Assets of IntelGenx Technologies Corp. (OTCPK:IGXT). May 29
IntelGenx Technologies Corp. Announces Board Resignations May 18
First quarter 2024 earnings released: US$0.023 loss per share (vs US$0.017 loss in 1Q 2023) May 17 See more updates IntelGenx Technologies Corp. Announces Resignation of Dwight Gorham as Chief Executive Officer IntelGenx Technologies Corp. announced delayed 10-Q filing Aug 15
ATAI Life Sciences AG entered into an agreement of purchase and sale to acquire the Assets of IntelGenx Technologies Corp. (OTCPK:IGXT). May 30
ATAI Life Sciences AG entered into an agreement of purchase and sale to acquire the Assets of IntelGenx Technologies Corp. (OTCPK:IGXT). May 29
IntelGenx Technologies Corp. Announces Board Resignations May 18
First quarter 2024 earnings released: US$0.023 loss per share (vs US$0.017 loss in 1Q 2023) May 17
Intelgenx Announces First Parkinson’S Disease Patients Dosed with Montelukast Versafilm® in Phase 2 ‘Montpark’ Clinical Trial Apr 10
IntelGenx Corp. Updates Status of Buprenorphine Buccal Film ANDA Apr 05
IntelGenx Technologies Corp., Annual General Meeting, May 07, 2024 Mar 22
New major risk - Financial position Mar 22
Full year 2023 earnings released: US$0.057 loss per share (vs US$0.065 loss in FY 2022) Mar 22
IntelGenx Technologies Corp. to Report Q4, 2023 Results on Mar 21, 2024 Mar 15
IntelGenx Technologies Corp. Announces Positive Results from Proof-Of-Concept Study to Assess the Palatability, Owner-Perceived Acceptability, and Ease of Repeated Administration of Intelgenx’s VetaFilm® Platform in Healthy Dogs and Cats Feb 06
IntelGenx Technologies Corp. Announces Changes to its Board of Directors Dec 04
IntelGenx Corp. Receives Approval to Conduct 'Montpark' Montelukast Versafilm Phase 2 Clinical Trial in Patients with Parkinson's Disease Nov 15
Third quarter 2023 earnings released: US$0.016 loss per share (vs US$0.015 loss in 3Q 2022) Nov 12
IntelGenx Technologies Corp. to Report Q3, 2023 Results on Nov 09, 2023 Nov 03
New minor risk - Shareholder dilution Oct 18
Gensco® Pharma and Intelgenx Announces Rizafilm Commercialization Update in the United States Sep 27
IntelGenx Corp. Provides Regulatory Update for Xiromed-Partnered Development Candidate, Buprenorphine Buccal Film Sep 21 IntelGenx Technologies Corp. announced that it expects to receive CAD 9.43492 million in funding from ATAI Life Sciences AG Sep 02
IntelGenx Technologies Corp. announced that it expects to receive CAD 8.42041 million in funding from ATAI Life Sciences AG Sep 01
Intelgenx Technologies Corp. Completes Enrollment for `Buena' Montelukast Versafilm® Phase 2A Clinical Trial in Patients with Mild to Moderate Alzheimer's Disease Aug 23
Second quarter 2023 earnings released: US$0.016 loss per share (vs US$0.017 loss in 2Q 2022) Aug 16
IntelGenx Technologies Corp. to Report Q2, 2023 Results on Aug 14, 2023 Aug 08
Intelgenx Corp. Completes Enrollment for 'Buena' Montelukast Versafilm®? Phase 2A Clinical Trial in Patients with Mild to Moderate Alzheimer's Disease Aug 02
Intelgenx Corp. Provides Update on Research Collaboration Evaluating Montelukast Versafilm for the Treatment of Parkinson's Disease Jul 26
Less than half of directors are independent Jul 25
IntelGenx Technologies Corp. Announces the Resignation of J. Bernard (Bernie) Boudreau from the Board of Directors Jul 23
First quarter 2023 earnings released: US$0.017 loss per share (vs US$0.017 loss in 1Q 2022) May 14
IntelGenx Technologies Corp. to Report Q1, 2023 Results on May 11, 2023 May 05
Full year 2022 earnings released: US$0.065 loss per share (vs US$0.068 loss in FY 2021) Mar 30
IntelGenx Corp. Receives FDA Pdufa Date for Rizafilm® Nov 23
Third quarter 2022 earnings released: US$0.015 loss per share (vs US$0.013 loss in 3Q 2021) Nov 16
Third quarter 2022 earnings released: US$0.015 loss per share (vs US$0.013 loss in 3Q 2021) Nov 12
IntelGenx Technologies Corp. to Report Q3, 2022 Results on Nov 10, 2022 Nov 04
IntelGenx Files Provisional U.S. Patent Application for Advanced Oral Film Formulation Improving Cannabinoid Onset of Action Nov 03
IntelGenx Receives FDA GDUFA Date for Xiromed-Partnered Development Candidate, Buprenorphine Buccal Film Oct 26
IntelGenx Corp. Submits Response to CRL from FDA for RIZAPORT VersaFilm Oct 19
IntelGenx Announces Enrollment Reaches Halfway Mark in ‘BUENA’ Montelukast VersaFilm Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease Sep 09
Second quarter 2022 earnings released: US$0.017 loss per share (vs US$0.017 loss in 2Q 2021) Aug 15
IntelGenx Technologies Corp. to Report Q2, 2022 Results on Aug 11, 2022 Aug 05
Less than half of directors are independent May 14
IntelGenx Technologies Corp. Elects Monika Trzcinska As Director May 13
IntelGenx Technologies Corp. to Report Q1, 2022 Results on May 12, 2022 May 06
First Patient Dosed in IntelGenx Technologies Corp. Resumed ‘Buena’ Montelukast Versafilm Phase 2A Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease Jan 22
Third quarter 2021 earnings released: US$0.013 loss per share (vs US$0.015 loss in 3Q 2020) Nov 12
Second quarter 2021 earnings released: US$0.017 loss per share (vs US$0.015 loss in 2Q 2020) Aug 06
IntelGenx Technologies Corp. announced that it has received $2.1 million in funding Aug 06
First quarter 2021 earnings released: US$0.02 loss per share (vs US$0.024 loss in 1Q 2020) May 16
Full year 2020 earnings released: US$0.065 loss per share (vs US$0.11 loss in FY 2019) Mar 27
IntelGenx Technologies Corp. to Report Q4, 2020 Results on Mar 25, 2021 Mar 19
IntelGenx Technologies Corp., Annual General Meeting, May 11, 2021 Mar 16
IntelGenx Receives USPTO Notice of Allowance for its Novel DisinteQTM-Based Disintegrating THC Oral Film Feb 18
IntelGenx Files Provisional U.S. Patent Application for Novel Vetafilmtm High Loading Oral Film Platform Feb 10
New 90-day high: €0.30 Feb 09
Intelgenx Receives First Purchase Order for Cbd Filmstrips from Heritage Cannabis Jan 09
New 90-day high: €0.22 Nov 24
Third quarter 2020 earnings released: US$0.015 loss per share Nov 14
IntelGenx Corp. Announces Publication of a Study Evaluating Montelukast’s Effect on Neurological Aging Nov 10
IntelGenx Technologies Corp. to Report Q3, 2020 Results on Nov 12, 2020 Nov 06
Heritage Cannabis Holdings Corp. Signs Letter of Intent with Intelgenx Technologies Corp. for Long-Term Cannabis Filmstrip Supply Agreement Oct 30
IntelGenx Technologies Corp. announced that it has received $1.2 million in funding Oct 16
First half earnings released Aug 14
IntelGenx Technologies Corp. to Report Q2, 2020 Results on Aug 13, 2020 Aug 07 Shareholder Returns 0IL DE Pharmaceuticals DE Market 7D 0% -2.5% -2.6% 1Y 16.3% -15.6% 6.9%
See full shareholder returns
Return vs Market: 0IL exceeded the German Market which returned 0.4% over the past year.
Price Volatility Is 0IL's price volatile compared to industry and market? 0IL volatility 0IL Average Weekly Movement n/a Pharmaceuticals Industry Average Movement 5.4% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.2% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 0IL's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 0IL's volatility change over the past year.
About the Company IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression.
Show more IntelGenx Technologies Corp. Fundamentals Summary How do IntelGenx Technologies's earnings and revenue compare to its market cap? 0IL fundamental statistics Market cap €26.46m Earnings (TTM ) -€10.01m Revenue (TTM ) €953.47k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0IL income statement (TTM ) Revenue US$1.05m Cost of Revenue US$1.75m Gross Profit -US$694.00k Other Expenses US$10.34m Earnings -US$11.03m
Last Reported Earnings
Mar 31, 2024
Earnings per share (EPS) -0.063 Gross Margin -66.03% Net Profit Margin -1,049.48% Debt/Equity Ratio -103.7%
How did 0IL perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/08/14 23:24 End of Day Share Price 2024/05/17 00:00 Earnings 2024/03/31 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources IntelGenx Technologies Corp. is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Benjamin Haynor Aegis Capital Corporation Douglas Loe Echelon Wealth Partners Inc. Christian Orquera First Berlin Equity Research GmbH
Show 5 more analysts 
